Zika Virus NS1, Recombinant (Zika Virus Nonstructural Protein 1)

Zika virus was first discovered in Ughanda in 1947 in monkeys infected by the virus through bites from of infected Aedes species mosquitos. Zika virus has become a highly researched disease due to increase in incidences from 2007 to 2016, when the virus spread eastward, across the Pacific Ocean to the Americas. In 2015–16 Zika virus epidemic reached pandemic levels. The Zika NS1 protein composes the majority of the virion surface and it is involved with replication, such as host cell binding and membrane fusion.

Many people infected with Zika virus will have mild or no symptoms while others will have fever, rash, joint pain, or conjunctivitis. People rarely die from Zika virus. Pregnant woman can pass Zika virus to her fetus causing microcephaly and other severe fetal brain defects.

Source:
Recombinant protein corresponding to Zika Virus NS1, expressed in E. coli.

Molecular Weight:
~44kD

Assay Information:
This protein binds to Zika converted human serum polyclonal antibodies and cross reacts with Dengue virus converted human serum polyclonal antibodies.

Applications:
Suitable for use in ELISA, Western Blot and Lateral Flow. Other applications not tested.

Recommended Dilution:
ELISA: 1-2ug/ml protein range for titering Dengue virus converted human polyclonal antibodies
Lateral Flow: 1-2mg/ml (1-2ul/cm)
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Aliquot to avoid repeated freezing and thawing and store at -70°C. Aliquots are stable for 6 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.